ClinicalTrials.gg
TerminatedNCT03164980COMPASSUpdated Mar 20, 2025Results posted

QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer

A Phase 4 interventional study of Trabectidin (Yondelis) in Quality of Life, Ovarian Cancer and Recurrent Ovarian Carcinoma, sponsored by North Eastern German Society of Gynaecological Oncology. Terminated at 21 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by North Eastern German Society of Gynaecological Oncology · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
A total of 204 patients were planned to be randomized. Due to slow recruitment of the trial, the recruitment was prematurely terminated after randomization of the 89th patient.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing trabectedin in Ovarian Neoplasms — none open to participants now, none under way, none of them phase 3. Trabectedin · Ovarian Neoplasms.

Enrollment
8th of 13
89 · median 100
Started
2018
the only one that year
Phase 4
Only one
of the 13
Registered
12th of 13
by date
Lead sponsor
1 of 13
North Eastern German Society of Gynaecological Oncology

Among the 13 studies testing trabectedin in Ovarian Neoplasms, this one is the 8th largest by enrollment, is the only one that started in 2018, is the only one in phase 4, and was the 12th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 13 studies testing trabectedin in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About trabectedin

Trabectedin: first FDA approval 2015 (YONDELIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing trabectedin in Ovarian Neoplasms as a file.
02

Study summary

This is a multicenter, randomized, controlled, open-label study including patients with recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer.

The main scope of the trial is to evaluate QoL during chemotherapy comparing trabectedin/PLD with other standard platinum-based chemotherapy in platinum-sensitive disease.

Read the detailed description

This is a multicenter, randomized, controlled, open-label study including patients with recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer.

The main scope of the trial is to evaluate QoL during chemotherapy comparing trabectedin/PLD with other standard platinum-based chemotherapy in platinum-sensitive disease.

Patients with recurrent, platinum-sensitive, ovarian, fallopian tube and peritoneal cancer will be stratified according to surgery for relapse (R0 vs. R1/2 resection) vs. no surgery in the same setting and age (\< 75 years vs. ≥ 75 years), and randomized 1:1 to receive either trabectedin/PLD (Arm A) or one of 3 platinum-based standard therapies without bevacizumab (Arm B, "other standard therapy"). In case of randomization to "other standard therapy", the investigator has the choice between carboplatin/PLD, carboplatin/gemcitabine and carboplatin/paclitaxel. Patients in both treatment arms will receive chemotherapy up for 6 cycles or until disease progression (PD), unacceptable toxicities or patient's wish to stop therapy, whichever occurs first.

03

Conditions studied

  • Quality of Life
  • Ovarian Cancer
  • Recurrent Ovarian Carcinoma

Keywords

  • Quality of life
  • ovarian cancer
  • platinum sensitive
  • recurrent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged ≥ 18 years
  2. Patients with confirmed diagnosis of epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube cancer who received ≥1 prior chemotherapy
  3. Patients must be eligible for platin-containing therapy; Patient is defined as platin-sensitive when considered for platin-containing therapy by the investigator. The time frame from end of prior therapy until disease progression alone is not pivotal for study participation. Patients without a platin-containing regimen in the previous line who are also eligible for platin-containing regime are also appropriate for participation
  4. (ECOG) performance status of ≤ 2
  5. Adequate baseline organ function as defined as

    • Leucocytes > 3.0 x 109/l
    • count > 100 x 109/l
    • (ANC) ≥1500/mm3
    • ≥ 9 g/dl
    • Alkaline Phosphatase (AP) ≤ 2.5 × (consider hepatic isoenzymes 5 nucleotidase or gamma glutamyl transpeptidase (GGT), if the elevation could be osseous in origin)
    • (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN
    • Creatinine-Clearance ≥ 60 ml/min ( formula or Cockroft \& Gault formula)
    • Serum creatinine ≤ 1.5 mg/dl
    • Creatine phosphokinase (CPK) ≤ 2.5 × ULN
    • Total \< ULN
  6. Women of should use or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study medication or be surgically sterile.
  7. Adequate cardiac function defined as (LVEF) ≥ 50% as determined by echocardiogram
  8. Patients must provide written prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up assessments and procedures.

Exclusion criteria

Exclusion criteria

  1. Only , which influence the prognosis
  2. Any unstable or serious concurrent condition (e.g. active infection requiring systemic therapy).
  3. Chemotherapy or radiation therapy or tumor embolization within 2 weeks prior to the first dose of study drug or planned during study participation.
  4. Patients who have disease. Refractory disease is defined if relapse occurs \<4 months after beginning of platin-containing therapy.
  5. to the active substance or to any of the of study drug
  6. Findings from and/or assessment of which indicate an anthracycline-related cardiotoxic process which contradicts administration of liposomal doxorubicin in accordance with the requirements of the SmPC of PLD.
  7. Biological therapy, immunotherapy, hormonal therapy or treatment with an agent within 14 days (for bevacizumab, 30 days) prior to the first dose of study drug.
  8. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
  9. Participation in another clinical study with experimental therapy within the 30 days before start of and during treatment. Participation in a non-interventional study should be discussed with sponsor and NC beforehand.
  10. Patients in a closed institution according to an authority or court decision (AMG § 40, Abs. 1 No. 4)
  11. Patients who are depending on the sponsor/CRO or investigational site as well as on the investigator.
  12. Pregnancy or lactation period, or planning to become pregnant within 7 months after the end of treatment.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Arm A

    PLD followed by Trabectedin. Treatment is repeated every 3 weeks for 6 cycles or until disease progression.

    Drug: Trabectidin (Yondelis)

  • Experimental
    Arm B

    * Carboplatin/PLD * Carboplatin/Gemcitabine * Carboplatin/Paclitaxel Patients will be treated for 6 cycles or until PD, unacceptable toxicity or patient's wish to discontinue, whichever occurs first.

    Drug: Trabectidin (Yondelis)

Interventions

  • DrugTrabectedinStudies of TrabectedinTrabectedin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel

06

What researchers measure

Primary outcomes

  1. Difference in Quality of Life (QoL)

    The difference in QoL is defined as change of the mean score of the Trial Outcome Index (TOI) from baseline (TOI at randomization) compared to end of treatment (TOI at EOT) and is calculated as follows: Difference TOI = TOI at EOT - TOI at baseline. 1. equals to 0 meaning no change in quality of life at EOT compared to baseline 2. \>0 meaning a detoriated quality of life at EOT compared to baseline. (The higher the number, the higher the detoriation.) 3. \<0 meaning an improved quality of life at EOT compared to baseline. (The lower the number, the higher the improvement.) TOI is calculated as mean of subscores concerning functional scales (e.g. physical function) and symptomal scales (e.g. body image, chemotherapy side effects, attitude to disease/treatment). Scores of each scale are transformed and ranges between 0-100. High scores for functional scales and symptomal scales meaning a low level of functioning and a high level of symptomatology/problems, respectively.

    Time frame: 12 month (from baseline to end of treatment)

Secondary outcomes

  1. Progression-free Survival

    Progression-free survival was defined as time (months) from randomization until date of the first occurrence of progression or recurrence, as determined by the investigator using CT criteria, or death from any cause.

    Time frame: 18 month

  2. Overall Survival

    Overall survival was defined as time from randomization until date of death to any cause.

    Time frame: through study completion, up to 3 years

07

Results

Posted Mar 20, 2025
Limitations and caveats
Due to slow recruitment of the trial, the recruitment was prematurely terminated after randomization of the 89th patient.

Participant flow

recruitment period:01.02.2018 - 28.03.2023

Participant flow — Overall Study
MilestoneArm AArm B
Started4544
Completed4441
Not completed13

Outcome measures

PrimaryDifference in Quality of Life (QoL)

The difference in QoL is defined as change of the mean score of the Trial Outcome Index (TOI) from baseline (TOI at randomization) compared to end of treatment (TOI at EOT) and is calculated as follows: Difference TOI = TOI at EOT - TOI at baseline. 1. equals to 0 meaning no change in quality of life at EOT compared to baseline 2. \>0 meaning a detoriated quality of life at EOT compared to baseline. (The higher the number, the higher the detoriation.) 3. \<0 meaning an improved quality of life at EOT compared to baseline. (The lower the number, the higher the improvement.) TOI is calculated as mean of subscores concerning functional scales (e.g. physical function) and symptomal scales (e.g. body image, chemotherapy side effects, attitude to disease/treatment). Scores of each scale are transformed and ranges between 0-100. High scores for functional scales and symptomal scales meaning a low level of functioning and a high level of symptomatology/problems, respectively.

Time frame:
12 month (from baseline to end of treatment)
Reported as:
Mean · units on a scale
Difference in Quality of Life (QoL)
units on a scaleArm AArm B
TOI at randomization (baseline)31.1 ± 15.628.7 ± 14.7
TOI at EOT36.9 ± 18.134.4 ± 16.6
Difference TOI: randomization over EOT6.5 ± 12.85.5 ± 12.7
SecondaryProgression-free Survival

Progression-free survival was defined as time (months) from randomization until date of the first occurrence of progression or recurrence, as determined by the investigator using CT criteria, or death from any cause.

Time frame:
18 month
Reported as:
Median · months
Progression-free Survival
monthsArm AArm B
Progression-free Survival8.2 (5.8 to 11.2)11 (9.0 to 13.6)
SecondaryOverall Survival

Overall survival was defined as time from randomization until date of death to any cause.

Time frame:
through study completion, up to 3 years
Reported as:
Median · months
Overall Survival
monthsArm AArm B
Overall Survival14.9 (10.4 to 35.2)19.9 (11.2 to 30.7)

Adverse events

Collected over through study completion, up to 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A40/44 (90.9%)20/44 (45.5%)40/44 (90.9%)
Arm B38/41 (92.7%)17/41 (41.5%)41/41 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventArm AArm B
AscitesGeneral disorders0/444/41
IleusGastrointestinal disorders4/442/41
Neutrophil count decreasedBlood and lymphatic system disorders3/442/41
Platelet count decreaseBlood and lymphatic system disorders2/442/41
DiarrheaGastrointestinal disorders2/441/41
SepsisGeneral disorders2/440/41
Worsening of general conditionGeneral disorders2/441/41
Urinary tract infectionRenal and urinary disorders0/441/41
Thromboembolic eventGeneral disorders0/441/41
DyspnoeRespiratory, thoracic and mediastinal disorders1/441/41
Most frequent other events
Most frequent other events
EventArm AArm B
Peripheral sensory neuropathyNervous system disorders9/4411/41
VomitingGastrointestinal disorders10/446/41
InsomniaGeneral disorders5/448/41
Hot flashesGeneral disorders3/447/41
Dry skinGeneral disorders3/444/41
HypokalemiaBlood and lymphatic system disorders4/440/41
MyalgiaGeneral disorders4/443/41
Stomach painGeneral disorders0/442/41
Weight lossGeneral disorders2/440/41

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm AArm BTotal
Mean60.3 ± 10.964.9 ± 9.662.5 ± 10.5
Age, Customized
Age, Customized(Participants)Arm AArm BTotal
< 70 years362763
>= 70 years81422
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BTotal
Female444185
Male000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Arm AArm BTotal
Count of participants——0
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m²)Arm AArm BTotal
Mean25.3 ± 5.226.2 ± 5.525.7 ± 5.4
ECOG
ECOG(Participants)Arm AArm BTotal
0171330
1272754
2011
3000
4000
5000
Localization of the primary tumor
Localization of the primary tumor(participants)Arm AArm BTotal
Primary peritoneal carcinoma347
Primary ovarian carcinoma373471
Tube carcinoma437
Histology of primary tumor
Histology of primary tumor(participants)Arm AArm BTotal
Clear cell235
Mucinous011
Serous423779

6 further baseline measures are reported on the registry.

08

Study locations

21 sites
  • Universitätsklinikum Aachen
    Aachen, 52074, Germany
  • Sankt Gertrauden-Krankenhaus
    Berlin, 10713, Germany
  • Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum
    Berlin, 13353, Germany
  • Praxis Krebsheilkunde für Frauen
    Berlin, 13597, Germany
  • Medizinisches Zentrum Bonn Friedensplatz
    Bonn, 53111, Germany
  • Universitätsklinikum Brandenburg an der Havel
    Brandenburg an der Havel, 14770, Germany
  • Studien GbR Braunschweig
    Braunschweig, 38100, Germany
  • Städtisches Klinikum Dessau
    Dessau, 06847, Germany
  • Frauenklinik Carl Gustav Carus
    Dresden, 01307, Germany
  • Onkologische Schwerpunktpraxis
    Dresden, 01307, Germany
  • Krankenhaus Nordwest gGmbH
    Frankfurt, 60488, Germany
  • Universitätsklinikum Freiburg
    Freiburg, 79106, Germany
  • ZAGO am Helios Klinikum Krefeld
    Krefeld, 47805, Germany
  • Universitätsfrauenklinik Leipzig
    Leipzig, 04103, Germany
  • Universitätsklinik der Johannes Gutenberg-Universität Mainz
    Mainz, 55131, Germany
  • Ruppiner Kliniken GmbH
    Neuruppin, 16816, Germany
  • Sana Klinikum Offenbach
    Offenbach, 63069, Germany
  • Klinikum Südstadt Rostock
    Rostock, 18059, Germany
  • Caritas Klinikum St. Theresia
    Saarbrücken, 66113, Germany
  • Krankenhaus Saarlouis vom DRK
    Saarlouis, 66740, Germany
  • Christliches Klinikum Unna gGmbH
    Unna, 59423, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Aug 2023, 66 months.

Results were first posted in Mar 2025, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2017
First posted
May 24, 2017
StartActual
Feb 1, 2018
Primary completionActual
Aug 8, 2023
CompletionActual
Aug 8, 2023
Results first posted
Mar 20, 2025
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03164980
Lead sponsor
North Eastern German Society of Gynaecological Oncology
Collaborators
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, PharmaMar
Responsible party
Sponsor
First posted
May 24, 2017
Start date
Feb 1, 2018
Primary completion
Aug 8, 2023
Completion
Aug 8, 2023
Results posted
Mar 20, 2025
Last update
Mar 20, 2025

Study contacts

Jalid Sehouli, Prof.
principal investigator · Charite University, Berlin, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trabectedin

Start the discussion